Theravance Biopharma, Inc. Property, Plant and Equipment, Gross
Theravance Biopharma, Inc. (TBPH) had Property, Plant and Equipment, Gross of $29.72 million as of 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization
us-gaap:PropertyPlantAndEquipmentGross · last filed 2026-03-23
- 2025-12-31: Property, Plant and Equipment, Gross $29.72M.
- 2024-12-31: Property, Plant and Equipment, Gross $29.82M.
- 2023-12-31: Property, Plant and Equipment, Gross $30.65M.
- 2022-12-31: Property, Plant and Equipment, Gross $44.71M.
| Period end | Property, Plant and Equipment, Gross |
|---|---|
| 2025-12-31 | $29.72M 10-K · filed 2026-03-23 |
| 2024-12-31 | $29.82M 10-K · filed 2026-03-23 |
| 2023-12-31 | $30.65M 10-K · filed 2025-03-07 |
| 2022-12-31 | $44.71M 10-K · filed 2024-03-01 |
| 2021-12-31 | $52.15M 10-K · filed 2023-03-01 |
| 2020-12-31 | $62.23M 10-K · filed 2022-02-28 |
| 2019-12-31 | $60.21M 10-K · filed 2021-02-26 |
| 2018-12-31 | $62.87M 10-K · filed 2020-02-27 |
| 2017-12-31 | $56.87M 10-K · filed 2019-02-28 |
| 2016-12-31 | $52.70M 10-K · filed 2018-02-28 |
| 2015-12-31 | $52.11M 10-K · filed 2017-03-01 |
| 2014-12-31 | $64.13M 10-K · filed 2016-03-11 |
| 2013-12-31 | $62.04M 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |